Investigation of the Effects of Relaxation Exercises on Neuropathic Pain, Fatigue and Sleep Quality
1 other identifier
interventional
88
1 country
1
Brief Summary
Relaxation exercises are an important factor in improving diabetes management and quality of life. Diet, exercise, medication and insulin therapy are important components of diabetes management. Among the goals that relaxation exercises should achieve is not only to provide information but also to ensure the patient's active participation in treatment by improving their application skills. Progressive Relaxation Exercises (PGE) are among the effective improvement techniques in the care process. Type 2 diabetes is a common metabolic disease and its chronic complications include neuropathic pain, fatigue and sleep disorders. Nurses play an important role in the care of these patients and the management of such symptoms is at the center of nursing practice. As a result, examining the effects of relaxation exercises on neuropathic pain, fatigue and sleep quality for patients with type 2 diabetes can increase the effectiveness of non-pharmacological approaches in nursing care and improve the quality of life of patients. Such studies have the potential to increase the quality of care and patient satisfaction by supporting the evidence-based practices of nurses. Hypotheses of the Study Hypothesis (H0): Progressive relaxation exercise has no effect on neuropathic pain, fatigue, and sleep quality of individuals with Type 2 diabetes. Hypothesis (H1): Progressive relaxation exercise has an effect on the neuropathic pain level of individuals with Type 2 diabetes. Hypothesis (H2): Progressive relaxation exercise has an effect on the fatigue level of individuals with Type 2 diabetes. Hypothesis (H3): Progressive relaxation exercise has an effect on the sleep quality of individuals with Type 2 diabetes. In light of all this information, the proposed study aimed to investigate the effects of relaxation exercises applied to study groups formed with diabetic patients on neuropathic pain, sleep quality and fatigue.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable type-2-diabetes
Started Jan 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 20, 2025
CompletedFirst Submitted
Initial submission to the registry
January 21, 2025
CompletedFirst Posted
Study publicly available on registry
January 27, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 7, 2026
CompletedJanuary 22, 2026
January 1, 2026
2 months
January 21, 2025
January 21, 2026
Conditions
Outcome Measures
Primary Outcomes (3)
S-LANSS Neuropathic Pain Scale
The S-LANSS pain score is based on the patient's assessment of the worst pain they have felt in the past week. This scale consists of a total of 7 questions; the first 5 questions are about pain symptoms, while the last 2 questions are aimed at determining the presence of allodynia (pain in response to a stimulus that is normally painless) and decreased pain sensation. The questions are answered only with "yes" or "no". Patients can receive a score between 0 and 24 on the test. The test results of patients who score 12 or higher support neuropathic pain, while the results of patients who score below 12 indicate non-neuropathic pain. (Bennett et al., 2005; Weingarten et al., 2007) The validity and reliability study of the S-LANSS Neuropathic Pain Scale was conducted in 2008 by Dr. Emine Rabia KOÇ. The reliability coefficients (Cronbach alpha value) between the items in the 1st and 2nd applications of the S-LANSS pain score were calculated as 0.74. The correlation coefficients for each
6 weeks
FACIT- (Fatigue) Scale
The total score range of the scale is between 0 and 52. A high total score indicates that the patient's fatigue is low, while a low total score indicates that the patient's fatigue is high. Items 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, and 13 of the scale are reverse scored, while items 7 and 8 are subject to a direct scoring system. The Cronbach's alpha coefficient of the scale was found to be 0.98. In the item analysis results of the scale, all correlations between the items were significantly high. Exploratory factor analysis methods were used to determine the construct validity of the scale, and the factor loading values of all items were found to be between 0.61 and 0.81. According to the factor analysis results, unlike the original scale, two sub-dimensions were found in the Turkish version of the scale. A general score total of less than 30 indicates severe fatigue.
6 weeks
Pittsburg Sleep Quality (PSQI) Scale
This scale consists of a total of 24 questions; 19 of these include the individual's own sleep experience, while 5 are answered by the spouse or roommate. Question 19 of the scale does not affect the results. The PSQI includes seven different components that evaluate subjective sleep quality, sleep onset time, sleep duration, sleep efficiency, sleep problems, use of sleeping pills, and daily functioning level. Each component is scored between 0 and 3, and the total score of the scale varies between 0 and 21. (MY, 1996; Roth \& Drake, 2004) If the total score of the PSQI is 5 or higher, it reflects poor sleep quality. The Cronbach's Alpha internal consistency coefficient was found to be 0.80. The diagnostic sensitivity of this scale was determined as 89.6% and the specificity as 86.5%.
6 weeks
Study Arms (2)
intervention group
EXPERIMENTALProgressive relaxation exercises will be applied to the experimental group.
no intervention group
NO INTERVENTIONThe control group will not receive any intervention.
Interventions
Researchers will teach individuals pge exercises to help them relax
Eligibility Criteria
You may qualify if:
- Those diagnosed with Type II DM for at least six months,
- Those aged between 18 and 65,
- Those who are literate,
- Those taking insulin and oral antidiabetic treatment,
- Those without a psychiatric illness,
- Those without any communication problems (vision, hearing, or speech),
- Those not using sleeping pills,
- Those with a Pittsburgh Sleep Quality Index average score of 5 or higher,
- Those with an S-LANSS average score of 12 or higher,
You may not qualify if:
- Those with a diabetic foot wound,
- Those with an amputation,
- Those with a malignant disease,
- Those with COPD or asthma,
- Those who discontinued the Progressive Relaxation Exercise program
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University, Ataturk University Campus, 25030 Yakutiye
Erzurum, Erzurum, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
eren k Kılıç
Ataturk University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- lecturer
Study Record Dates
First Submitted
January 21, 2025
First Posted
January 27, 2025
Study Start
January 20, 2025
Primary Completion
March 20, 2025
Study Completion
February 7, 2026
Last Updated
January 22, 2026
Record last verified: 2026-01